IL15 and T-cell non-Hodgkin lymphoma: Trials have also been initiated in patients with chronic lymphocytic leukemia with obinutuzumab in combination with rhL-15 (NCT03759184) and IL-15 with avelumab (anti-PD-L1) in patients with mature T-cell lymphoma (NCT03905135) and renal cell cancer (NCT04150562), and IL-15 with mogamulizumab (anti-CCR4, NCT04185220) in patients with ATL and cutaneous T-cell lymphoma.